15 results about "Retina Neovascularization" patented technology

The invention discloses application of an IL-8 inhibitor to treatment of diabetic retinopathy patients. The molecular mechanism of IL-8 in the diabetic retinopathy generation and development process is deeply explored, a theoretical basis is provided for SB225002 to influence the generation and development of diabetic retinopathy through inflammation, and a feasible direction is provided for diabetic retinopathy treatment and targeted retinal neovascularization treatment drugs.

The invention discloses application of a growth hormone receptor antagonist and a nucleic acid molecule in preparation of a medicine for preventing or treating retinal neovascularization diseases, and relates to the technical field of retinal neovascularization. The invention finds that the growth hormone receptor antagonist or the blocking reagent can effectively intervene the occurrence and development of the neovascular retina disease and improve the symptom of the disease. In addition, the transcription level of the encoding gene of the growth hormone receptor is reduced in a gene editing mode, and the pathological vascular change of the retinal neovascular disease can be effectively improved by knocking out the retina GHR, so that the pathological neovascular growth of the retina is reduced, and vascular exudation and inflammatory response are reduced. The invention provides a new direction for the treatment of retinal neovascular diseases, and provides a new choice for patients intolerant or unresponsive to anti-VEGF (Vascular Endothelial Growth Factor) treatment.

Benzyl derivative compounds having peroxisome proliferator-activated receptor alpha (PPARα) agonist activity, kits and compositions containing such compounds, and methods of using them to enhance PPARα activity to treat diseases and / or conditions involving inflammation and / or angiogenesis, particularly diseases and / or conditions of the eye such as, but not limited to, retinal inflammation, retinal neovascularization, retinal vascular leakage, retinopathy of prematurity, diabetic retinopathy, age-related macular degeneration, and diabetic macular edema.

The invention discloses a retina neovascularization segmentation method based on a dual-path multi-scale attention network, and belongs to the technical field of medical information processing, and the method comprises the steps: determining a WF-OCTA image of a retina neovascularization, drawing a segmentation mask on the WF-OCTA image, and obtaining input data; multi-scale features of input data are extracted through an encoder-decoder, jump connection is established, and multi-stage input feature tensors are obtained; performing two-way multi-scale feature mining on the input feature tensor, capturing form information and context information in parallel, and obtaining a residual enhanced output feature tensor; statistical space-spectrum attention enhancement is carried out on the residual error enhancement output feature tensor, channel re-calibration and statistical magnitude-based space fine positioning are carried out, and a statistical enhancement output feature tensor is obtained; and carrying out fusion statistics on the output feature tensor in the decoding path, carrying out step-by-step reconstruction, obtaining a pixel-level probability graph, carrying out training by using mixed loss, and outputting a segmentation result.

Microparticulate (MP) formulations formed from one or more poly(hydroxyacid) polymers having a molecular weight ranging from 5kD to 60kD, and one or more active agents are injected into the eye of a subject to address eye disorders. The MP formulations assure high drug loading and extended delivery of the active agent of six to twelve months. The active agents may include peroxisome proliferator-activated receptor alpha (PPARα) signaling agonists such as PPARα agonist A190 (IUPAC name 3-((4-((4-fluorobenzyl)oxy)- 3- methylbenzyl)amino)benzoic acid). The formulations have therapeutic and protective effects against retinal degeneration diseases such as age-related macular degeneration (AMD), but may also be used for treating or relieving the symptoms of retinal inflammation, retinal neovascularization, retinal vascular leakage, retinopathy of prematurity (ROP), diabetic retinopathy (DR), and diabetic macular edema (DME).

The application provides an animal model of high-oxygen-induced retinal neovascular disease and a preparation method thereof. The method comprises the following steps: placing a mouse born for 3-7 days in an environment with an oxygen concentration of 75-85%, and maintaining for 10-30 days. The method can successfully induce a long-acting retinal neovascular disease model, has a high modeling rate, fewer complications, more persistent retinal neovascular lesions, and a model duration of 55 days. The animal model provides a more optimal model for exploring long-acting anti-retinal neovascular related drugs.

The invention discloses application of a tetrahedral framework nucleic acid-resveratrol compound in preparation of a medicine for treating retinal neovascular diseases. According to the invention, resveratrol molecules are coupled to a DNA single-stranded skeleton of tFNAs through an electrostatic adsorption method, so that the tetrahedral framework nucleic acid-resveratrol compound (tFNAs-RSV) is formed. Researches show that when the tFNAs-RSV compound is used for treating retinal neovascular diseases, the four targets of resisting retinal pathological neovascularization, improving retinal perfusion, promoting retinal physiological vascularization and protecting a retinal nerve vascular unit (RNVU) which are difficult to achieve simultaneously by single medication of tFNAs or RSV are achieved, and a synergistic interaction effect is exerted; and a breakthrough solution is provided for precise treatment of the retina neovascular diseases.

Benzyl derivative compounds having peroxisome proliferator-activated receptor alpha (PPAR alpha) agonistic activity, kits and compositions comprising such compounds, and methods of their use to enhance PPAR alpha activity for the treatment of diseases and / or disorders involving inflammation and / or angiogenesis, in particular ocular diseases and / or disorders, such as inflammatory diseases and / or angiogenesis. Such as, but not limited to, retinal inflammation, retinal neovascularization, retinal vascular leakage, preterm retinopathy, diabetic retinopathy, age-related macular degeneration, and diabetic macular edema.

The invention relates to an application of leucine-rich transmembrane fibronectin 2 (FLRT2) in preparation of a medicine for intervening abnormal retinal neovascularization. The research finds that the leucine-rich transmembrane fibronectin 2 can promote the generation of retinal neovascularization, and the generation of pathological abnormal retinal neovascularization can be inhibited by inhibiting the expression of the leucine-rich transmembrane fibronectin 2; the leucine-rich transmembrane fibronectin 2 can be used as a new target for preventing and / or intervening eye retinal neovascularization related diseases, and provides a new direction and strategy for intervention of retinal abnormal neovascularization related diseases. The leucine-rich transmembrane fibronectin 2 inhibitor is any one or any combination of small interfering ribonucleic acid selected from small interfering ribonucleic acid 1, small interfering ribonucleic acid 2, small interfering ribonucleic acid 3, small interfering ribonucleic acid 4, small interfering ribonucleic acid 5 and small interfering ribonucleic acid 6.

The invention relates to application of a microglial cell TAK1 gene as a target spot in treatment of retinal neovascular diseases. The invention finds that by specifically knocking out the microglial cell TAK1 gene, the number of neovascular clusters under pathological conditions can be effectively reduced, migration and proliferation of retinal tissue neovascular endothelial cells are inhibited, pathological retinal neovascularization is effectively inhibited, but the physiological angiogenesis capability of human retinal microvascular endothelial cells is not influenced. Therefore, retina neovascular diseases including diabetic retinopathy, premature infant retinopathy, retinal vein occlusion, familial exudative vitreoretinopathy and the like can be effectively treated by specifically knocking out the microglial cell TAK1 gene. The invention provides a new target and a new idea for the treatment of retinal neovascular diseases.

The invention discloses a retina neovascularization automatic typing method based on a scale perception network, and belongs to the field of medical image intelligent analysis and computer-aided diagnosis, and the method comprises the steps: inputting an OCTA image of a retinopathy patient in a proliferation period, inputting the OCTA image into a pre-trained scale perception typing model, carrying out image standardization preprocessing on the OCTA image by a self-adaptive preprocessing module in the scale perception parting model to obtain a standardized image; the deep topological feature extraction backbone network performs multi-scale blood vessel morphological feature extraction based on the standardized image; and the prediction output module outputs new blood vessel form typing results according to the extracted multi-scale blood vessel form characteristics, and the typing results comprise a single trunk branch type, a multi-source mesh type and an anastomosis ring type. According to the method, rapid, accurate and objective automatic typing of the new blood vessel in the OCTA image is realized, and auxiliary decision support is provided for individualized accurate treatment of proliferation phase retinopathy.

The present application relates to a novel compound and its use as therapeutically active substance in the treatment and / or prevention of diseases which involve the retinal pigment epithelium, in particular diseases which lead to atrophy, degeneration or death of the retinal pigment epithelium, which can also lead to atrophy or loss of photoreceptors and / or retinal neovascularization.

The application discloses a retinal neovascularization segmentation method based on a double-path multi-scale attention network, and belongs to the technical field of medical information processing. The method comprises the following steps: determining a WF-OCTA image of retinal neovascularization, drawing a segmentation mask on the WF-OCTA image, and obtaining input data; extracting multi-scale features of the input data through an encoder-decoder and establishing a skip connection to obtain a multi-level input feature tensor; performing double-path multi-scale feature mining on the input feature tensor, capturing morphological information and context information in parallel, and obtaining a residual enhanced output feature tensor; performing statistical spatial-spectral attention enhancement on the residual enhanced output feature tensor, performing channel re-labeling and spatial fine positioning based on a statistical quantity, and obtaining a statistical enhanced output feature tensor; fusing the statistical enhanced output feature tensor in a decoding path and gradually reconstructing to obtain a pixel-level probability map, training the pixel-level probability map through a hybrid loss, and outputting a segmentation result.

To provide compositions and methods for treatment of ocular disease associated with angiogenesis.SOLUTION: The present disclosure provides compositions and methods for the treatment of ocular diseases associated with angiogenesis, particularly wet age-related macular degeneration. Ocular vascular diseases such as age-related macular degeneration and diabetic retinopathy are due to abnormal choroidal or retinal neovascularization respectively. Since the retina consists of well-defined layers of neuronal, glial, and vascular elements, relatively small disturbances such as those seen in vascular proliferation or edema can lead to significant loss of a visual function. Inherited retinal degenerations, such as Retinitis Pigmentosa, are also associated with vascular abnormalities, such as arteriolar narrowing and vascular atrophy.SELECTED DRAWING: None

The invention provides application of BPS in treatment of retinal neovascularization related diseases, and relates to the field of biological medicine. The BPS has a remarkable inhibition effect on pathological endothelial cell migration and angiogenesis in a macrophage and human retina microvascular endothelial cell co-culture model, has a good application prospect in preparation of drugs for treating diseases related to retinal neovascularization, and provides a research tool for research on the diseases related to retinal neovascularization.